id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-270388-nozh463l	Damiani, M.	Extracorporeal Cytokine Hemadsorption in Severe COVID-19 Respiratory Failure	2020-06-29		.txt	text/plain	1051	73	53	Despite the extracorporeal cytokine hemadsorption device CytoSorb was granted FDA emergency approval for critically ill COVID19 patients, to our knowledge no published studies are currently available to support its use. 4 An alternative treatment able to reduce circulating cytokines in critically ill patients is CytoSorb (Aferetica srl, Italy), a device containing adsorbent polymer beads designed to irreversibly remove cytokines currently used for septic shock and other conditions where elevated levels of cytokines are present. Despite the lack of published results, based on bench performance testing and reported clinical experience, CytoSorb was granted FDA emergency approval for critically ill SARS-CoV-2 patients on April 10, 2020. . https://doi.org/10.1101/2020.06.28.20133561 doi: medRxiv preprint C-reactive protein (CRP) levels and respiratory parameters including the PaO2/FiO2 ratio (P/F) were assessed daily. Further studies are required to assess if CytoSorb can improve the clinical outcome of critically ill patients.	./cache/cord-270388-nozh463l.txt	./txt/cord-270388-nozh463l.txt